[Retracted] Osimertinib Improves Overall Survival in Patients with Leptomeningeal Metastases Associated with EGFR-Mutated Non-Small-Cell Lung Cancer Regardless of Cerebrospinal Fluid T790M Mutational Status

Figure 2

(a) Overall survival from LM diagnosis for the total population. (b) Kaplan–Meier curve of the OS of patients in the osimertinib and the first- or second-generation EGFR-TKI treatment groups. (c) Kaplan–Meier curve of the PFS of patients in osimertinib and the first- or-second generation EGFR-TKI treatment groups. (d) Kaplan–Meier estimates of OS according to osimertinib treatment and T790M mutation status. (e) Kaplan–Meier estimates of OS according to osimertinib treatment and CSF T790M mutation status. (f) Kaplan–Meier estimates of OS according to different osimertinib dosages. OS: overall survival, PFS: progression-free survival, TKI: tyrosine kinase inhibitor, CI: confidence interval, and HR: hazard ratio.

(a)

(b)

(c)

(d)

(e)

(f)